Stem-Cell Gene Therapy for Sickle Cell Advances Toward Clinical Trials

UCLA Health

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle-cell disease to treat the illness. The study was led by Donald Kohn, MD, professor of pediatrics and of microbiology, immunology and molecular genetics.

 

Sickle-cell disease causes the body to produce misshapen red blood cells that form like the crescent-shaped blade of a sickle, which hinders blood flow and deprives the body’s organs of oxygen. Dr. Kohn introduced an anti-sickling gene into the hematopoietic stem cells to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle. The breakthrough gene-therapy technique for sickle-cell disease is scheduled to begin clinical trials early next year.

 

Dr. Kohn’s autologous gene-therapy approach is a revolutionary alternative to current sickle-cell disease treatments, which include transplanting patients with donor hematopoietic stem cells. Such transplants offer a potential cure for sickle-cell disease, but due to the serious risks of rejection, only a small number of patients have undergone this procedure, and it is usually restricted to children with severe symptoms.

 

Dr. Kohn and colleagues found that in the laboratory, the hematopoietic stem cells produced new non-sickled blood cells at a rate sufficient for significant clinical improvement for patients. The new blood cells survive longer than sickled cells, which also could improve treatment outcomes.

 

More than 90,000 patients in the U.S. have been diagnosed with sickle-cell disease. It is caused by an inherited mutation in the beta-globin gene that makes red blood cells change from their normal shape, which is round and pliable, into a rigid, sickle-shaped cell. Normal red blood cells are able to pass easily through the tiniest blood vessels, carrying oxygen to organs throughout the body. But due to their rigid structure, sickled blood cells get stuck in the small capillaries.

 

“ß-globin Gene Transfer to Human Bone Marrow for Sickle Cell Disease,” Journal of Clinical Investigation, July 1, 2013

More From UCLA Health >>
Read Next Article >>
Got grapes? UCLA researchers have demonstrated how resveratrol, an antioxidant derived from grapes...
UCLA has been tapped by the Defense Advanced Research Projects Agency to spearhead an innovative...
Harry Campbell
Neurologist Bruce Miller calls tau—a floppy, free-form protein—“the holy grail of dementia.” That...
Physicians have long assumed that ovarian cancer—one of the deadliest cancers among women—...
Wrong-level spine surgeries—when a surgeon accidentally operates on the wrong vertebra—occur with...
Photo by Sam Kaplan; Copyright Sam Kaplan
In 2012, when the journal Science published a study by a group of Cleveland researchers touting a...
Photo by Movus; http://www.gettyimages.com
Patients who come to Johns Hopkins for epilepsy surgery sometimes require a prequel to their...
Copyright Getty Images
In the late 1990s, the process of isolating genes from the chromosomes in which they reside was...
Photo by Sergey Anatolievich Pristyazhnyuk; copyright Getty Images
The human body has many natural barriers intended to prevent microorganisms, diseases, and toxins...
Illustration by Brian Stauffer
 When Fred Lesikar arrived at the hospital in October 2009 suffering sharp pain in his upper back,...